The majority of prior studies for the COVID-19 vaccinations -writ large- generate an efficacy range around 60 to 70 percent in prevention of COVID hospitalization. The efficacy for virus infection is essentially nil. The vaccine does nothing to prevent infection or transmission; their only claims are now a reduction in hospitalization rates.
Therapeutics, preventative medicines and healthy lifestyle choices to avoid negative outcomes, have been mostly ignored, often ridiculed, and largely downplayed by politicians, media and Big Pharma. Instead their preferred collective strategy has been a massive, overemphasized and almost exclusive effort to force vaccinations as the only medical option for SARS-CoV-2 infections.
The most studied and widespread therapeutic treatment on a global scale has been the use of an oral antiviral pill known as Ivermectin and a regime of supportive medications. Japan and India have embraced the Ivermectin protocol with reported large scale success rates.
However, the U.S., Europe and Australia have focused exclusively on treating and chasing the SARS-CoV-2 virus with vaccines for the virus and boosters for the variants.
Today Pfizer, the #1 vaccine maker on a global scale, is introducing their version of a pill form of therapeutic. With Ivermectin, a Merck product, costing somewhere around 30¢/dose, it appears Pfizer sees an opening for a $xx/dose pill option to enhance their growing profit margin. It is interesting to note the Pfizer study for their pill was conducted on a non-vaccinated population.
(VIA ABC) – A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results released Friday by the pharmaceutical company.
In a study of more than 1,200 COVID-19 patients with a higher risk of developing serious illness, people who took Pfizer’s pills were far less likely to end up in the hospital compared to people who got placebo pills.
[…] “Having an oral therapy is critically important,” said Dr. Carlos Del Rio, the executive associate dean and a global health expert at the Emory School of Medicine.
“If we can get patients to start treatment early before they progress to severe illness and unfortunately death, everyone wins in the fight against COVID,” said Dr. Simone Wildes, a board-certified infectious disease physician at South Shore Health and an ABC News contributor. Infectious disease specialists stressed that these pills are not a replacement for a vaccine — by far the safest and most effective way to reduce the risk of being hospitalized with COVID-19.
But they may make a big difference if given quickly to people after getting COVID-19, especially the immune compromised, or in places where a vaccine is not available.
Pfizer’s pill-based treatment “would be a good drug for patient with COVID and high risk of progression, vaccinated or not,” said Del Rio, “although the vaccinated were not included in this study.” (read more)
Both Merck and Pfizer are requesting emergency use authorization for their pill form therapeutics.